La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Kiora Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Kiora Pharmaceuticals..

Kiora Pharmaceuticals (NASDAQ:KPRX) Azioni, Catena delle Opzioni

Kiora Pharmaceuticals

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals Inc

TD Cowen analyst Vivien Azer downgrades Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) from Buy to Hold and lowers the price target from $50 to $48.

News

Downgrades

Price Target

Analyst Ratings

BF/B

TD Cowen Downgrades Brown-Forman to Hold, Lowers Price Target to $48

WIIM

CHTR

Charter Communications shares are trading higher after Benchmark maintained a Buy rating on the stock and raised its price target from $440 to $450.

Management

CLBT

Cellebrite CEO Yossi Carmil To Step Down After Nearly 20 Years; Executive Chairman Thomas E. Hogan To Serve As Interim CEO Pending New Appointment

Piper Sandler analyst Christopher Raymond maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Overweight and raises the price target from $4 to $5.

KPTI

Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $5

American Electric Power Company, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) reported the&nbsp;third quarter revenue of&nbsp;$5.42 billion,&nbsp;missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769709/aep-reports-third-quarter-2024-earnings-introduces-new-growth-rate-and-capital-plan" rel="noreferrer noopener">consensus of&nbsp;$5.434 billion</a>.
Commercial load increased more than&nbsp;10%&nbsp;year-over-year through the&nbsp;third quarter. The company projects commercial load to grow an average of 20% annually over the next three years on the basis of customer contracts signed so far.
Total energy distribution fell 1.0% in the Vertically Integrated Utilities segment and&nbsp;rose 4.1% in the Transmission &amp; Distribution Utilities segment.&nbsp;
Adjusted operating earnings rose to&nbsp;$985.4 million from&nbsp;$923.8 million a year ago.&nbsp;
Adjusted operating earnings from Vertically Integrated Utilities rose to&nbsp;$572.4 million from&nbsp;$520.0 million the prior year, and AEP Transmission Holdco grew to&nbsp;$214.7 million from&nbsp;$202.9 million&nbsp;in the prior&nbsp;year&#8217;s quarter.
Adjusted EPS&nbsp;of&nbsp;$1.85 <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beat the consensus of&nbsp;$1.80</a>.
FY24&nbsp;Outlook: American Electric Power narrowed adjusted operating earnings per share&nbsp;guidance&nbsp;from&nbsp;$5.53 &#8211; $5.73&nbsp;to $5.58 &#8211; $5.68<a target="_blank" href="https://www.benzinga.com//node/40038448" rel="noreferrer noopener"> vs.&nbsp;consensus of&nbsp;$5.62</a>.
The company sees FY25 adjusted EPS of $5.75 &#8211; $5.95 <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">vs consensus of $5.98</a>. The company now expects a long-term growth rate outlook of 6% to 8% (vs. 6% to 7% prior).
Bill Fehrman, AEP president and chief executive officer, said, &#8220;AEP has a strong foundation and significant growth opportunities ahead, and we are confident in our ability to execute our strategy and deliver on our promises. This confidence is reflected in our new&nbsp;6%-8%&nbsp;long-term growth rate and expanded capital investment plan of&nbsp;$54 billion&nbsp;over the next five years, along with our commitment to a strong balance sheet.&#8221;
Investors can gain exposure to the stock via&nbsp;Listed Funds Trust TrueShares Eagle Global Renewable Energy Income ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNWZ#NYSE">RNWZ</a>)&nbsp;SPDR Select Sector Fund – Utilities&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>).
Price Action: AEP shares are down 0.90% at $99.50 premarket at the last check Wednesday.
Photo by american-public-power-association- for Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41254312/hurricane-milton-descends-on-florida-analysts-warn-of-impact-on-disney-nexteras-flo" target="_blank" rel="noreferrer noopener">Hurricane Milton Descends On Florida: Analysts Warn Of Impact On Disney, NextEra&#8217;s Florida Power &amp; Light, Regional Banks</a></li>
</ul>

Earnings

Equities

Large Cap

Guidance

RNWZ

American Electric Power Q3: EPS Beat, Revenue Miss, 10% Commercial Load Jump & More

Ontrak, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>), a leading AI-powered and telehealth-enabled behavioral healthcare company, today announced a continuing expansion of its strategic partnership with Sentara Health Plans in the Commonwealth of Virginia.

OTRK

Ontrak Health Expands Behavioral Health Solutions With Sentara Health Plans In The Commonwealth Of Virginia For Commercial And Marketplace Populations

Piper Sandler analyst John Barnidge maintains Horace Mann Educators (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMN#NYSE">HMN</a>) with a Neutral and raises the price target from $36 to $42.

Piper Sandler Maintains Neutral on Horace Mann Educators, Raises Price Target to $42

Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) ("Bit Digital" or the "Company"),&nbsp;a global platform for high-performance computing ("HPC") infrastructure and digital asset production headquartered in New York, announced its unaudited digital asset production, HPC services revenue, and corporate updates for the month of October 2024.
Corporate Highlights for October 2024
<ul>
<li>The Company had 256 servers actively generating revenue from its initial Bit Digital AI contract, as of October 31, 2024. The Company earned approximately $4.3 million of unaudited revenue from this contract during the month of October 2024.</li>
<li>In October 2024, the Company produced 52.2&nbsp;BTC, a 1.4% increase compared to the prior month.</li>
<li>The Company's active hash rate was approximately 2.43 EH/s as of October 31, 2024.</li>
<li>Treasury holdings of&nbsp;BTC and ETH were 781.2 and 27,503.4 with a fair market value of approximately $54.8 million and $69.2 million, respectively, on October 31, 2024.</li>
<li>The&nbsp;BTC equivalent[1] of our digital asset holdings as of October 31, 2024, was approximately 1,768.6 or approximately $124.2 million.</li>
<li>The Company had cash and cash equivalents of $79.8 million and total liquidity (defined as cash and cash equivalents,&nbsp;USDC, and the fair market value of digital assets) of approximately $203.9 million, as of October 31, 2024.</li>
</ul>

BTBT

Bit Digital, Inc. Announces Monthly Production Update For October 2024; Produced 52.2 BTC, A 1.4% Increase MoM

Emerson Electric shares are trading higher after Deutsche Bank and Baird raised their respective price targets on the stock.

Rosenblatt analyst Mike Genovese maintains Infinera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFN#NASDAQ">INFN</a>) with a Neutral and maintains $6.65 price target.

INFN

Rosenblatt Maintains Neutral on Infinera, Maintains $6.65 Price Target

Piper Sandler analyst Jason Bednar maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and raises the price target from $165 to $180.

MASI

Piper Sandler Maintains Overweight on Masimo, Raises Price Target to $180

Piper Sandler analyst Harsh Kumar maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Overweight and lowers the price target from $100 to $85.

MCHP

Piper Sandler Maintains Overweight on Microchip Technology, Lowers Price Target to $85

United States Antimony Corporation ("USAC", or the "Company"), (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#NYSE">UAMY</a>), a leader in the processing of critical minerals, has announced today that it has successfully staked and recorded an additional 24 new claims totaling 3,840 acres (6 square miles) on Alaska State lands near Stibnite Creek, located in the Tok area of Alaska. This strategic move places UAMY in a known antimony-rich region along the Alaska Highway, approximately 200 miles southeast of Fairbanks. With this addition, the Company now controls a total of 93 claims totaling 14,880 acres in Alaska, most of which is either associated with antimony or other critical minerals.

UAMY

United States Antimony Corporation Further Expands Alaska Mining Land Ownership Position With Acquisition Of Stibnite Creek Antimony Claims; No Financial Terms Disclosed

Piper Sandler analyst Biren Amin maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Neutral and lowers the price target from $40 to $32.

APLS

Piper Sandler Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $32

TD Cowen analyst Robert Moskow upgrades Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Sell to Hold and raises the price target from $155 to $170.

Upgrades

TD Cowen Upgrades Clorox to Hold, Raises Price Target to $170

Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.44) by 52.27 percent. This is a 43.24 percent increase over losses of $(0.37) per share from the same period last year. The company reported $14.97 million in sales this quarter.

Earnings Beats

BRNS

Barinthus Biotherapeutics Q3 EPS $(0.21) Beats $(0.44) Estimate, Sales $14.97M

Rosenblatt analyst Hans Mosesmann maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and maintains $90 price target.

Rosenblatt Maintains Buy on Microchip Technology, Maintains $90 Price Target

Dividends

ADP Increases Quarterly Dividend From $1.40 To $1.54 Per Share

Greystone Housing Impact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHI#NYSE">GHI</a>) reported quarterly losses of $(0.23) per share. The company reported quarterly sales of $24.346 million which missed the analyst consensus estimate of $25.908 million by 6.03 percent. This is a 8.04 percent decrease over sales of $26.474 million the same period last year.

Earnings Misses

Greystone Housing Impact Q3 2024 GAAP EPS $(0.23), Sales $24.346M Miss $25.908M Estimate

TD Cowen analyst Robert Moskow downgrades MGP Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) from Buy to Hold and lowers the price target from $66 to $50.

MGPI

TD Cowen Downgrades MGP Ingredients to Hold, Lowers Price Target to $50

Maxim Group analyst Michael Okunewitch maintained a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report) yesterday and set a price target o...

Buy Rating on Kiora Pharmaceuticals Amid Strong Financials and Promising Clinical Trials

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report), retaining the price target of $2.00. ...

Buy Rating for Kiora Pharmaceuticals Bolstered by Strong Financials and Promising Clinical Trial Data

The latest announcement is out from Kiora Pharmaceuticals (KPRX). The Company has made headlines by announcing Ms. Walters-Hoffert's appointment to...

Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance

Kiora Pharmaceuticals GAAP EPS of -$0.53 beats by $0.33

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kiora Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/kprx-stock-quote/">KPRX</a>) just reported results for the second quarter of 2024.<ul><li>Kiora Pharmaceuticals reported earnings per share of -53 cents. This was above the analyst estimate for EPS of -81 cents.</li><li>The company reported revenue of $20,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/kprx-stock-earnings-kiora-pharmaceuticals-for-q2-of-2024/">KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024

Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report), with a price target of $27.00....

Buy Rating on Kiora Pharmaceuticals: Strong Financials and Promising KIO-301 Progress

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report), retaining the price target of $10.00....

Buy Rating on Kiora Pharmaceuticals Amid Promising Clinical Trials and Strong Financials

Kiora Pharmaceuticals ( ($KPRX) ) has issued an update. Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial of...

Comments

Kiora Pharmaceuticals

Kiora Pharmaceuticals (KPRX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO